Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 6, 2012, Pages 992-997

  Raps, M ^a   Helmerhorst, F ^a   Fleischer, K ^b   Thomassen, S ^c   Rosendaal, F ^a   Rosing, J ^c   Ballieux, B ^a   Van Vliet, H ^a,d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d CATHARINA HOSPITAL   (Netherlands)

Author keywords

Activated protein C resistance; Contraceptive; Sex hormone binding globulin; Venous thrombosis

Indexed keywords

ACTIVATED PROTEIN C; CONTRACEPTIVE AGENT; COPPER INTRAUTERINE DEVICE; CYPROTERONE; DESOGESTREL; DROSPIRENONE; ETHINYLESTRADIOL; ETONOGESTREL; LEVONORGESTREL; NORELGESTROMIN; SEX HORMONE BINDING GLOBULIN;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR RISK; FEMALE; HIGH RISK POPULATION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; NORMAL HUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSDERMAL PATCH; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; INTRAUTERINE DEVICES; MIDDLE AGED; NETHERLANDS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROTEIN C; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN; THROMBIN; TRANSDERMAL PATCH; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 84861653721     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04720.x     Document Type: Article

References (39)

1. Vandenbroucke JP, Rosing J, Bloemenkamp KWM, Middeldorp S, Helmerhorst FM, Bouma BN, Rosendaal FR. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 1527-34.
2. Rosendaal FR, van Hylckama Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens and thrombosis. J Thromb Haemost 2003; 1: 1371-80.
3. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339: b2921.
4. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing a thirdgeneration progestagen. Lancet 1995; 346: 1593-6.
5. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346: 1582-8.
6. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890.
7. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.
8. van Hylckama Vlieg A, Middeldorp S. Hormone therapies and venous thromboembolism: where are we now? J Thromb Haemost 2011; 9: 257-66.
9. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011; 342: d2151.
10. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011; 342: d2139.
11. Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ 2011; 183: E1319-25.
12. Lidegaard O, Nielsen LH, Skovlund CW, Skjeldestad FE, Lokkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011; 343: d6423.
13. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. 2012. Food and Drug Administration. Accessed 22 October 2011.
14. Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, Meijers JC, Bouma BN, Buller HR, Prins MH, Tans G. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354: 2036-40.
15. van Vliet HA, Winkel TA, Noort I, Rosing J, Rosendaal FR. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb Haemost 2004; 2: 2060-2.
16. Tchaikovski SN, van Vliet HA, Thomassen MC, Bertina RM, Rosendaal FR, Sandset PM, Helmerhorst FM, Tans G, Rosing J. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Thromb Haemost 2007; 98: 1350-6.
17. Tans G, van Hylckama Vlieg A, Thomassen MC, Curvers J, Bertina RM, Rosing J, Rosendaal FR. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003; 122: 465-70.
18. Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 2002; 81: 482-90.
19. Gardner DG. Greenspan's Basic & Clinical Endocrinology, 8th edn. Columbus, OH: McGraw-Hill, 2007.
20. van der Vange N, Blankenstein MA, Kloosterboer HJ, Haspels AA, Thijssen JH. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception 1990; 41: 345-52.
21. Knopp RH, Broyles FE, Cheung M, Moore K, Marcovina S, Chandler WL. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel. Contraception 2001; 63: 1-11.
22. Kemmeren JM, Algra A, Meijers JC, Tans G, Bouma BN, Curvers J, Rosing J, Grobbee DE. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood 2004; 103: 927-33.
23. van Rooijen M, Silveira A, Hamsten A, Bremme K. Sex hormone-binding globulin - a surrogate marker for the prothrombotic effects of combined oral contraceptives. Am J Obstet Gynecol 2004; 190: 332-7.
24. van Vliet HA, Tchaikovski SN, Rosendaal FR, Rosing J, Helmerhorst FM. The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC). Thromb Haemost 2009; 101: 691-5.
25. van Vliet HA, Rodrigues SP, Snieders MN, van der Meer FJ, Frolich M, Rosendaal FR, Rosing J, Helmerhorst FM. Sensitivity to activated protein C during the menstrual cycle in women with and without factor VLeiden. Thromb Res 2008; 121: 757-61.
26. Fleischer K, van Vliet HA, Rosendaal FR, Rosing J, Tchaikovski S, Helmerhorst FM. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study. Thromb Res 2009; 123: 429-35.
27. World Health Organization. Medical Eligibility Criteria for Contraceptive Use, 4th edn. Geneva: WHO, 2009. Accessed 2009, last updated 2010.
28. Tchaikovski S. Hormone-induced changes in the coagulation system. Thesis, Maastricht University, 2009. Universitaire Pers Maastricht, Maastricht, the Netherlands.
29. Johnson JV, Lowell J, Badger GJ, Rosing J, Tchaikovski S, Cushman M. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Obstet Gynecol 2008; 111: 278-84.
30. Jick SS, Hagberg KW, Hernandez RK, Kaye JA. Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism. Contraception 2010; 81: 16-21.
31. van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010; 30: 2297-300.
32. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35microg of ethinyl estradiol. Contraception 2006; 73: 223-8.
33. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007; 109: 339-46.
34. Jick SS, Kaye JA, Li L, Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35μg of ethinyl estradiol. Contraception 2007; 76: 4-7.
35. Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000; 39: 233-42.
36. Ortho-McNeil-Janssen Pharmaceuticals. US product information ortho-Evra®. 2009.
37. Devineni D, Skee D, Vaccaro N, Massarella J, Janssens L, LaGuardia KD, Leung AT. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. J Clin Pharmacol 2007; 47: 497-509.
38. Stanczyk FZ, Grimes DA. Sex hormone-binding globulin: not a surrogate marker for venous thromboembolism in women using oral contraceptives. Contraception 2008; 78: 201-3.
39. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1998; 877: 1-89.